Drug profile · INN
ceftibuten dihydrate
CEDAX
ceftibuten dihydrate (CEDAX) is a bacterial penicillin-binding protein inhibitor. Route of administration: oral. Current US regulatory status: approved.
Drug details — ceftibuten dihydrate
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
ceftibuten dihydrate (CEDAX) is a bacterial penicillin-binding protein inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial penicillin-binding protein inhibitor
Primary target: Bacterial penicillin-binding protein
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is ceftibuten dihydrate?
ceftibuten dihydrate (CEDAX) is a bacterial penicillin-binding protein inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for ceftibuten dihydrate?
CEDAX is a marketed brand name for ceftibuten dihydrate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ceftibuten dihydrate?
ceftibuten dihydrate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.